GlassScriptPhysician profile
Victor Mwansa
NPI 1811194244
$17,890.20
in general payments reported to CMS, 2019-2025
34 companies · $3,743 in 2025
The $3,743 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $335 · 2021: $468 · 2022: $4,512 · 2023: $3,376 · 2024: $4,735 · 2025: $3,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,967 · Travel and Lodging: $5,786 · Grant: $95.00 · Education: $5.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,966.72 |
| Travel and Lodging | $5,786.42 |
| Grant | $95.00 |
| Education | $5.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,528.11 | 2019-2025 | Versacross Access Solution, Watchman, General - Structural Heart |
| Abbott Laboratories | $4,749.87 | 2019-2025 | Triclip, Aveir, Amplatzer |
| Siemens Medical Solutions USA, INC. | $827.67 | 2023 | |
| Abiomed | $758.89 | 2022-2025 | Impella |
| Janssen Pharmaceuticals, INC | $693.64 | 2019-2024 | Xarelto |
| Philips North America LLC | $688.15 | 2025 | Intracardiac Undivided |
| Pfizer INC. | $679.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.60 | 2019-2025 | Jardiance |
| Amgen INC. | $537.09 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $521.11 | 2023-2025 | Corevalve Evolut R, Micra, Linq II |
| Novartis Pharmaceuticals Corporation | $450.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $329.43 | 2023-2025 | Verquvo |
| Edwards Lifesciences Corporation | $290.62 | 2024 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $246.41 | 2021-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $167.89 | 2019-2025 | Lifevest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $108.02 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $84.25 | 2025 | Amvuttra |
| Shockwave Medical, INC | $80.45 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $75.67 | 2019-2024 | Farxiga, Brilinta |
| Kiniksa Pharmaceuticals International, Plc | $64.12 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $63.24 | 2019-2022 | |
| Stryker Corporation | $55.31 | 2025 | Flowtriever |
| Scpharmaceuticals INC. | $53.31 | 2024 | |
| Cardiovascular Systems INC. | $46.70 | 2022-2023 | Diamondback Coronary |
| Novo Nordisk INC | $38.01 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $35.86 | 2022-2023 | |
| Inari Medical, INC. | $34.47 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Preventice Services, LLC | $31.82 | 2019 | |
| Cvrx, INC. | $22.61 | 2023 | Barostim Neo System |
| Grifols USA, LLC | $21.43 | 2021 | |
| Biocompatibles, INC. | $17.89 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.16 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $14.78 | 2020 | |
| Amarin Pharma, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Mwansa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.